Page 12 - Medication Guide News Today

First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for...

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 5, 2023--

/PRNewswire/ -- The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and...

The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments in child neurology. As part of this conference, UCB will present two late-breaking posters that shed...

/PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has...

/PRNewswire/ -- Galderma, the emerging pure-play dermatology category leader, today announced a new campaign to provide education and support for breast cancer...

Last week, FDA released a draft guidance, "Labeling for Biosimilar and Interchangeable Biosimilar Products" ("2023 Draft Guidance") that—when finalized—will revise and replace its July 2018...

Last week, FDA released a draft guidance, "Labeling for Biosimilar and Interchangeable Biosimilar Products" that—when finalized—will revise and replace its July 2018 final guidance...

/PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in...

Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and neurology, is pleased to announce that the U.S. Food and Drug Administration (FDA)...